Biocracked
Approach 2, lab in action, with palette D, bold color field.

Straight-on, slightly elevated close shot of a gloved hand in a pale nitrile glove holding a glass syringe with a fine needle. The syringe is filled with clear liquid and sits over a row of small glass vials in a matte white rack. The whole scene sits against a saturated tomato-red seamless backdrop. Soft, even studio light gives crisp highlights along the syringe barrel and the vial glass, plus gentle warm-red reflections on the surfaces. A thin electric green (#00e676) cap on one vial is the only small accent. The dosing markings on the syringe are blurred and unreadable. Shallow depth of field blurs the back vials into soft shapes. The mood is precise, clinical and investigational, with high contrast and a measured, careful feel. No text, no labels, no logos.
Research

Matsakaicin Magani na CBL‑514 – Menene Kimiyyar Sa?

Dr. Synapse · · 5 min read

Matsakaicin Magani na CBL‑514 – Menene Kimiyyar Sa?

Karanta wannan da farko: CBL‑514 wani ƙwayar magani ne da ake bincike ta hanyar allura a cikin gwaje‑gwajen likita. Ba allura ce da za a sha ba, ba ƙari ba, ba samfur da aka amince da shi ba, kuma ba shawarar likita ba ce. Adadin “600 mg” da ake gani a yanar gizo shi ne iyakar adadin da ake amfani da shi a kowanne magani a cikin tsarin gwaji – ba adadin da za a iya ci ko shan ba. (Lura: CBL‑514, ba “CL‑514”).

CBL‑514 kamfani ne daga Caliway Biopharmaceuticals kuma ana kiransa a matsayin ƙananan ƙwayar maganin allura da ke rage kitse. A takardun, ana bai wa majinyata allurar sub‑cutaneous a cikin ƙirjin ƙirji. Manufar da kamfanin ke bayyana (cikin rahotannin da ba a wallafa ba) ita ce kashe ƙwayoyin kitse (adipocytes) ta hanyar apoptosis. Ba zai ƙara saurin metabolism ba, ba “ƙone kitse” ba, kuma ba ragin nauyin jiki gaba ɗaya ba. Takardun ba su bayyana tsarin sinadarin ba.

Mataki na ɗaya: Binciken Phase 2a na ƙayyade ƙima

Binciken da aka yi shi ne Goodman et al., Aesthetic Surgery Journal 2022 (PMC9384315). An gudanar da shi buɗe‑label ba tare da placebo ba, kuma ƙaramar ƙungiya ne: n=43, an raba su 7 / 18 / 18 a tsakanin matakan ƙima uku.

An ayyana ƙimar a kan kowanne centimita murabba'i (cm²) na fata da aka magance, a kan yanki na 150 cm²:

Matsakaicin ƙima (mg/cm²) Jimillar adadin da aka yi amfani da shi (150 cm²)
1.2 180 mg
1.6 240 mg
2.0 300 mg

An yi allura 60 a cikin makonni 2. Adadin mg kawai shi ne ƙimar ƙarfi a kan yanki da aka ninka. Misali, 2.0 mg/cm² × 150 cm² = 300 mg.

Takardar ta ba da rahoton ragin kashi‑kashi (ITT) ga kowanne rukunin, kuma masu karatu su duba takardar don ganin cikakken ƙididdiga. Lambar da aka fi ambata ita ce 24.96 %. Wannan sakamakon na Per‑Protocol (PP) ne, ga rukunin 2.0 mg/cm², a biyo‑bayan farko, inda aka samu −119.82 mL na ragin kitse. Sakamakon PP yana ƙididdige ne kawai mahalarta da suka bi tsarin da aka tsara, ba ya wakiltar sakamako ga dukkan mahalarta ba.

Mataki na biyu: Phase 2 da aka gwada da placebo

Babban takarda itace Gold et al., Aesthetic Surgery Journal 2025;45(6):611‑620 (PMC12080885; PubMed; DOI). An gudanar da shi a matsayin randomized, single‑blind (mahalarta kawai) kuma placebo‑controlled, a cibiyoyi biyar a Amurka da Australia.

Matsakaicin ƙima an tsaya a 2.0 mg/cm². Duk abin da ya canza shine:

  • Yankin magani: 300 cm² (ninka yanki na Phase 2a).
  • Yawan allura: 25‑50 a kowanne magani, bisa shawarar mai bincike dangane da adadin kitse a ƙirjin.
  • Kowane allura: 2.4 mL, an rarraba su da tazara na 2.45 cm.
  • Iyaka: har 600 mg a kowanne magani (2.0 mg/cm² × 300 cm²).
  • Tsarin lokaci: har zuwa magani 4 a makonni 4, tare da biyo‑bayan a makonni 4 da 8 bayan magani na ƙarshe.
  • Kamar yadda aka kwatanta: saline na yau da kullum da aka ba da a girman daidai.

An raba placebo (saline) da ƙididdiga 2:1.

Dalilin da yasa jimillar mg ba za a iya musanya su ba

Canjin daga 300 mg zuwa 600 mg ba yana nufin an ninka ƙimar magani a wani yanayi na halitta ba. ƙimar a kan yanki ta kasance guda: 2.0 mg/cm². Abin da ya canza shine yanki da aka yi magani, adadin allura, tazara tsakanin lokuta, da tsarin lokaci. Jimillar mg kawai tana da ma’ana idan an haɗa da waɗannan bayanai.

Saboda haka fassarar “600 mg” a matsayin ƙimar ƙari ba daidai ba ce. Lambar nan tana nuni ne ga iyaka ga jerin allura da aka tsara bisa yanki, ba ga abin da mutum zai sha ba a waje da wannan tsari.

Babu gwajin kai tsaye tsakanin ƙimar ƙima a Phase 2

Phase 2 ba ta raba mahalarta zuwa ƙimar ƙima daban‑daban ba tare da placebo ba. 2.0 mg/cm² an kulle shi bisa ga aikin farko. Don haka hujjar da aka samu daga gwajin placebo tana tallafawa wannan ƙimar guda, ba ƙirƙira sabon tsari ba. Kawai gwajin buɗe‑label na Phase 2a ne ke da matsakaicin ƙima uku, kuma ba shi da armar placebo.

Abin da Phase 2 ta gano a wannan tsari

Masu bincike sun ba da rahoton cikar manufofin farko da na biyu. A cikin nazarin ITT, 63.9 % (23/36) na mahalarta da suka samu CBL‑514 sun rasa aƙalla 150 mL na ragin kitse a ɓangaren ƙirji a biyo‑bayan mako 4, idan aka kwatanta da 17.4 % (4/23) a placebo. A mako 8, adadin ya kai 69.6 % (16/23) vs 0 % (0/16). Adadin mahalarta ya ragu saboda rashin cikakken bayanan biyo‑bayan.

Matsakaicin bambanci tsakanin ƙungiyoyi ya kasance −206.62 mL a mako 4 da −216.28 mL a mako 8. An ƙididdige girman kitse daga ultrasound a maki huɗu da yanki na 300 cm², ba a auna kai tsaye ba.

Mahimman gargadi:

  • Daga mahalarta 75 da aka yi magani, 37 (49.3 %) ba su kammala ba.
  • Ƙungiyar PP ita ce 30 kawai.
  • Mai tallafa ya taka rawa a ƙirƙira, nazari da rubutu.
  • Masu bincike ba su rufe ido ba.
  • Girman samfurin ƙanana ne, na bincike ne kawai.
  • Nauyin jiki bai canza sosai ba, don haka wannan rage girman kitse na wuri‑wuri ne, ba ragin nauyi ba.

Tsaro a matakan gwaji

An bi sahihan al'amuran tsaro ta hanyar rikodin abubuwan da suka faru bayan magani, gwajin jini, sigogi, ECG, duban jiki, da kuma amsoshin wurin allura da aka rubuta a matsayin al'amuran daban‑daban a kowane magani. Ayyukan wurin allura sune manyan abubuwan da za a iya tsammani daga tsari da ke da manyan injekshani a kowane zaman. Masu karatu su duba takardun don ganin adadin ainihi, ciki har da yawan zafi mai tsanani, maimakon dogaro da takaitattun bayanai. Daga mahalarta 37 da ba su kammala ba a Phase 2, huɗu sun bar saboda abubuwan da suka faru.

A Phase 2a, ƙungiyar bincike ta yi amfani da matakan kamar anesthetic, kankara, da antihistamine. Wannan ba shawarar likita ba ne, yana nuna yadda masu bincike suka sarrafa aikin gwaji, ba abin da kowa zai yi da kansa ba.

Takardun sun kuma lura da alamun lipids a wasu mahalarta da ke da manyan lipids tun farko. Wannan ƙaramar abu ne a cikin mutane kaɗan, ba a tabbatar da tasirin metabolic ba. Babu wani abu a cikin waɗannan gwaje‑gwajen da ya tabbatar da tasirin tsarin jiki na CBL‑514.

Abin da masu sha’awar “bio‑hacking” ya kamata su fahimta

Kimiyyar CBL‑514 ta ƙunshi gwaji ƙanana buɗe‑label da ya kwatanta ƙima uku a kan yanki, sannan babban gwaji single‑blind da ya yi amfani da ɗaya daga cikinsu (2.0 mg/cm²) a kan yanki mai faɗi tare da iyaka mafi girma a kowanne zaman. Karanta “600 mg” a matsayin ƙimar alama yana rasa duk wannan.

CBL‑514 ba a amince da shi ba, ba samfurin masu amfani ba, kuma wannan makala ba shawarwarin likita ba ne.

Original study

Read the original research on pmc.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

DS

Written by

Dr. Synapse

Dr. Synapse writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Approach 1, macro science, in palette D, bold color field.

Extreme close-up photograph of a cluster of fat cells (adipocytes) in tissue, shot like a stained microscopy image. Rounded, translucent, pearly-yellow lipid-filled cells press together in a honeycomb. Several in the center look collapsed and shriveled, with ruptured membranes and scattered droplets. A few fine threads of electric green (#00e676) fluorescent stain outline the cell walls. The camera is straight-on at shallow depth of field, with the background cells melting into soft blur. Bright, even transmitted light makes the membranes glow. The backdrop is a saturated magenta-to-tomato-red field that sets off the pale yellow cells. The mood is scrutinizing, skeptical and precise. No text, no labels.
research

Allurar rage kitsen CBL‑514: Menene kimiyya ke cewa?

BY DR. SYNAPSE ·

CBL‑514 ta wuce gwajin mataki na biyu da aka sarrafa placebo a mujallar *Aesthetic Surgery Journal*, inda marubuta suka ce ta cika manyan manufofin da aka saita. Sai dai wannan bitar na nuna dalilan da ya sa dole a duba ƙirar gwajin sosai: an yi amfani da blind guda ɗaya, masu bincike da mai tallafa ba su da ɓoye, kuma mai tallafa ya shiga ƙirƙira, tantancewa da rubuta sakamakon. Daga cikin mahalarta 75 da aka ba da magani, kawai 38 suka kammala, kuma ƙungiyar da aka yi nazari a kai ta ƙunshi mutane 30 kacal. An dakatar da bibiyar bayan makonni 8, kuma samfurin ya fi yawa mata da fararen fata. Wannan labarin zai fayyace abin da gwajin zai iya tabbatarwa, abin da ba zai iya ba, da dalilin da ya sa ba za a ɗauke shi a matsayin shawara ta likita ko hujja da aka amince da ita ba.

Approach 1, macro science, with Palette D, bold color field.

Extreme close-up microscopy-style photograph of a cluster of adipocytes (fat cells). Each is a translucent, pale yellow sphere with a thin membrane, and a few are shrunken and crinkled to suggest apoptosis. The cells sit against a saturated magenta backdrop. The camera is slightly above, at a shallow 30-degree angle, with a very shallow depth of field so the foreground cells are razor sharp and the rest melts into soft bokeh. Hard, clean side light from the left makes the membranes glisten and casts crisp magenta-tinted shadows. One tiny electric green fluorescent speck glows inside a single collapsing cell as a subtle accent. The mood is precise, clinical and curious, with a bold editorial feel. There is no text and no blue cast.
research

Allurar CBL-514 Lipolysis: Binciken Mataki na 2

BY DR. SYNAPSE ·

CBL‑514 wani allura ne da ake bincike don haifar da apoptosis na sel ɗin kitse (adipocytes) a cikin ciki. A gwajin mataki na 2 da aka gudanar a 2025 tare da mahalarta 76 da aka raba ta bazuwar, an samu raguwar ƙimar kitse da aka auna ta ultrasound idan aka kwatanta da saline, yayin da matsakaicin nauyin jiki ya tsaya ba tare da canji ba. Ƙididdigar ta gabatar da ƙirar gwajin, ƙimar 2 mg/cm², cikakkun bayanan tasiri da ƙananan lambobi, da hanyar DYRK1b/caspase da kamfanin ya ba da rahoto. An kuma bayyana iyakokin: ƙirar single‑blind, haɗin gwiwar mai tallafa, kusan 49 % rashin kammalawa, gajeren lokaci na bibiyar, da yawan samfurin mata.

**Approach 1 (macro science), Palette D (bold color field).**

Extreme close-up microscopy-style photograph of a cluster of fat cells (adipocytes), rendered as translucent, pearly spheres with thin membranes and tiny lipid droplets inside. One cell in the center is visibly shrinking and blebbing, its membrane crinkled and fragmenting into small beads, the look of apoptosis. A few of the surrounding cells are intact and glossy. The cells sit against a saturated tomato-red backdrop, so the pale yellow-cream spheres stand out sharply. The camera looks straight down at shallow depth of field, with the focal plane on the dying cell and the edges softly blurred. Soft, diffuse top light gives gentle highlights and warm shadows, with no blue cast. One thin electric green fluorescent ring around the central cell's nucleus is the only green accent. The mood is analytical, precise and quietly skeptical.
research

Ta yaya CBL‑514 ke aiki? Ilimin kimiyya

BY DR. SYNAPSE ·

CBL‑514 ba a nuna shi a matsayin maganin narkewar ko kona kitse ba. Da'awar da ake yi ita ce yana hanawa kinase DYRK1b aiki sannan ya tilastawa ƙwayoyin kitse shiga apoptosis ta hanyar caspase‑3 da Bax/Bcl‑2. Hujjar wannan zaɓi ta samo asali ne daga rahotannin kamfanin da ba a wallafa ba a takardun Phase 2a da Phase 2, kuma ba a fayyace takamaiman tsarin sinadarin ba. Gwajin Phase 2 na 2025 ya auna girman kitse da ultrasound, hotuna, da aminci, ba tare da ƙarin bayanai kamar biopsi ko caspase ba. Wannan labarin na nuni da bambanci tsakanin tunanin sel da abin da aka auna a ɗan adam, ciki har da yawan mutuwar mahalarta da tsarin single‑blind.

Approach: the human outcome. Palette: bold color field.

A close, slightly high three-quarter view of a bare abdomen, cropped at the ribs and hips with no face. A hand in an electric green (#00e676) nitrile glove pinches a fold of belly skin and holds a slim syringe with the needle just about to enter. Faint yellow-purple bruising near the injection site hints at the side effects. The torso fills the frame against a flat, saturated teal backdrop that contrasts with the warm skin tones. Soft, even studio light from the left gives gentle shadows and visible skin texture, with fine pores and small hairs. The syringe tip is in sharp focus and the background falls away. No text or markings anywhere. The mood is clinical, unsentimental and skeptical.
research

Shin CBL‑514 na ƙona mai ainihi? Ga abin da muka sani

BY HELIX WARD ·

Binciken mataki na biyu da aka gudanar a 2025 kan CBL‑514 bai nufin rage nauyin jiki ba; an duba ko alluran da aka yi a ƙirji za su iya rage aƙalla mililita 150 na kitse a ƙarƙashin fata ta hanyar ultrasound. Bayan makonni 8, kashi 69.6 % (16/23) na masu karɓar CBL‑514 sun cimma wannan ragi, yayin da babu ɗaya a rukunin placebo. Duk da haka, matsakaicin nauyin jiki bai ragu ba (ƙara 0.02 kg) kuma kusan rabi na mahalarta ba su kammala binciken ba. Martani a wurin allura ya kasance gama‑gari, ciki har da ƙura a fata a 71.4 % da zafi mai tsanani a 18.4 %. Wannan shine abin da binciken ya nuna da abin da bai nuna ba.

This page is available in